A 17.8-month median duration of response in a population that had burned through a median of four prior therapies — including, for most, a BTK inhibitor — is the number that reframes what iopofosine I 131 is actually doing in relapsed/refractory Waldenström macroglobulinemia. That figure comes from mature 12-month follow-up data in CLOVER WaM, now complete across all 55 per-protocol patients, and it matters precisely because the FDA asked for it. Cellectar didn’t generate this dataset opportunistically; regulators specified the follow-up threshold as a condition for the accelerated approval pathway. The data delivered.
The headline efficacy numbers hold up at scale: 83.6% ORR, 61.8% major response rate as the primary endpoint, and a 98.2% disease control rate. More clinically meaningful is what happened in the BTKi-exposed and BTKi-refractory subsets. In the 33 BTKi-refractory patients — the hardest corner of this disease — the major response rate was 63.6% with a median duration of response of 18.2 months and median PFS of 14.8 months. That isn’t degraded relative to the overall population; it’s essentially equivalent. The mechanism matters here: iopofosine is a phospholipid drug-conjugate that exploits cancer cell membrane biology, not a pathway inhibitor, which is why BTKi resistance doesn’t blunt its activity. Four fixed infusions, each approximately 30 minutes, with no significant bleeding events and infection rates below 10% — the tolerability profile in a heavily immunocompromised population isn’t a footnote.
The regulatory architecture is now in place. Surrogate endpoints with durability support, FDA-specified follow-up complete, and a $140 million financing round closed to fund both the NDA submission for accelerated approval and the confirmatory randomized trial targeting PFS as a primary endpoint in a post-BTKi, post-first-line population. Confirmatory trial initiation is set for Q4 2026. The ASCO presentation in late May will put post-BTKi data in front of a broader oncology audience at the moment when Cellectar needs institutional and clinical buy-in for enrollment.
The single number to track from here is the confirmatory trial’s enrollment rate once it opens. Accelerated approval without timely confirmatory completion is where small companies lose regulatory credibility — and in a rare disease with an estimated patient pool in the thousands, accrual velocity will determine whether the full approval story stays on schedule or fractures.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
